Two Reports Show Progress in Treatment Options for Chronic Disease
America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
With the population of Americans over 65 on the rise and life expectancy climbing, chronic diseases remain a principal threat to the health and productivity of older Americans, as well as to rising health care costs. Innovative medicines have led to major advances against many chronic diseases – and the robust discovery pipeline of new medicines portends continued progress for seniors and our health care system.
“Our ability to prevent, manage and treat chronic diseases has progressed dramatically in recent years, due in large part to the discovery and availability of new innovative medicines,” said PhRMA President and CEO John J. Castellani. “But we can’t rest on our laurels. The more than 400 medicines in the pipeline for diseases prevalent among older Americans have tremendous potential to improve and extend the lives of seniors, and reduce costly emergency room visits, hospitalizations and surgical procedures.”


By P., Piero D.D.S.



By Warren J. Potash




